Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
View Patent ↗(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.
1. A method of improving cognition in a patient suffering from Schizophrenia, comprising:
administering to said patient a daily dose in the range of between 0.1 mg to 3.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate; or (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride solvate.
3. The method of claim 2 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is administered to the patient.
4. The method of claim 3 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.
5. The method of claim 3 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.
6. The method of claim 5 , wherein the daily dose is in the range of between 0.3 mg to 1.5 mg.
7. The method of claim 5 , wherein the daily dose is in the range of between 0.7 mg to 1.25 mg.
8. The method of claim 5 , wherein the daily dose is in the range of between 1.0 mg to 3.0 mg.
9. The method of claim 5 , wherein the daily dose is in the range of between 1.5 mg to 2.5 mg.
10. The method of claim 5 , wherein the daily dose is in the range of between 1.75 mg to 2.25 mg.
11. The method of claim 5 , wherein the daily dose is in the range of between 2.0 mg to 3.0 mg.
12. The method of claim 1 , wherein the schizophrenia comprises a paranoid type, a disorganized type, catatonic type, or an undifferentiated type.
13. The method of claim 12 , wherein the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition.
14. A method of improving cognition in a patient suffering from Alzheimer's disease, comprising:
administering to said patient a daily dose in the range of between 0.1 mg to 3.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.
15. The method of claim 14 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate; or (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride solvate.
16. The method of claim 15 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is administered to said patient.
17. The method of claim 16 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.
18. The method of claim 16 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.
19. The method of claim 18 , wherein the daily dose is in the range of between 0.3 mg to 1.5 mg.
20. The method of claim 18 , wherein the daily dose is in the range of between 0.7 mg to 1.25 mg.
21. The method of claim 18 , wherein the daily dose is in the range of between 1.0 mg to 3.0 mg.
22. The method of claim 18 , wherein the daily dose is in the range of between 1.5 mg to 2.5 mg.
23. The method of claim 18 , wherein the daily dose is in the range of between 1.75 mg to 2.25 mg.
24. The method of claim 18 , wherein the daily dose is in the range of between 2.0 mg to 3.0 mg.
25. The method of claim 14 , wherein the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition.